These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 20213083)
1. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083 [TBL] [Abstract][Full Text] [Related]
2. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
3. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267 [TBL] [Abstract][Full Text] [Related]
4. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Li Y; Xu J; Chen L; Zhong WD; Zhang Z; Mi L; Zhang Y; Liao CG; Bian HJ; Jiang JL; Yang XM; Li XY; Fan CM; Zhu P; Fu L; Chen ZN Histopathology; 2009 May; 54(6):677-87. PubMed ID: 19438743 [TBL] [Abstract][Full Text] [Related]
5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA Breast J; 2009; 15(2):120-32. PubMed ID: 19292797 [TBL] [Abstract][Full Text] [Related]
7. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575 [TBL] [Abstract][Full Text] [Related]
8. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110 [TBL] [Abstract][Full Text] [Related]
9. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Yu H; Levesque MA; Clark GM; Diamandis EP Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775 [TBL] [Abstract][Full Text] [Related]
10. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695 [TBL] [Abstract][Full Text] [Related]
11. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124 [TBL] [Abstract][Full Text] [Related]
12. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911 [TBL] [Abstract][Full Text] [Related]
13. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM; J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968 [TBL] [Abstract][Full Text] [Related]
15. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405 [TBL] [Abstract][Full Text] [Related]
17. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Sullivan PS; Apple SK Breast J; 2009; 15(2):146-54. PubMed ID: 19292800 [TBL] [Abstract][Full Text] [Related]
18. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Di Saverio S; Gutierrez J; Avisar E Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874 [TBL] [Abstract][Full Text] [Related]
19. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of molecular classification of breast invasive ductal carcinoma. Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]